AAAAAA

   
Results: 1-17 |
Results: 17
URSODIOL PROPHYLAXIS AGAINST HEPATIC COMPLICATIONS OF ALLOGENEIC BONE-MARROW TRANSPLANTATION - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Authors: ESSELL JH SCHROEDER MT HARMAN GS HALVORSON R LEW V CALLANDER N SNYDER M LEWIS SK ALLERTON JP THOMPSON JM
Citation: Jh. Essell et al., URSODIOL PROPHYLAXIS AGAINST HEPATIC COMPLICATIONS OF ALLOGENEIC BONE-MARROW TRANSPLANTATION - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, Annals of internal medicine, 128(12), 1998, pp. 975
A RANDOMIZED, DOUBLE-BLIND COMPARISON OF SINGLE-DOSE AND DIVIDED MULTIPLE-DOSE DOLASETRON FOR CISPLATIN-INDUCED EMESIS
Authors: HARMAN GS OMURA GA RYAN K HAINSWORTH JD CRAMER MB HAHNE WF
Citation: Gs. Harman et al., A RANDOMIZED, DOUBLE-BLIND COMPARISON OF SINGLE-DOSE AND DIVIDED MULTIPLE-DOSE DOLASETRON FOR CISPLATIN-INDUCED EMESIS, Cancer chemotherapy and pharmacology, 38(4), 1996, pp. 323-328
FATAL CYCLOPHOSPHAMIDE CARDIOMYOPATHY - ITS CLINICAL COURSE AND TREATMENT
Authors: LEE CK HARMAN GS HOHL RJ GINGRICH RD
Citation: Ck. Lee et al., FATAL CYCLOPHOSPHAMIDE CARDIOMYOPATHY - ITS CLINICAL COURSE AND TREATMENT, Bone marrow transplantation, 18(3), 1996, pp. 573-577
GRAFT-VERSUS-HOST DISEASE AND SURVIVAL IN GRADED INCREMENTAL ADD-BACK(GIAB) FOR T-CELL DEPLETION-ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT), COMPARED TO 2-LEVEL ADD-BACK (TLAB)
Authors: LEE CK GINGRICH RD HARMAN GS HOHL RJ SVSEL IA FRANCY RJ AJRAM KA JOHANNSEN SM
Citation: Ck. Lee et al., GRAFT-VERSUS-HOST DISEASE AND SURVIVAL IN GRADED INCREMENTAL ADD-BACK(GIAB) FOR T-CELL DEPLETION-ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT), COMPARED TO 2-LEVEL ADD-BACK (TLAB), Blood, 88(10), 1996, pp. 3777-3777
RISK FACTOR-DEPENDENT MODULATION OF GRAFT-VERSUS-HOST DISEASE (GVHD) BY GRADED INCREMENTAL T-CELL ADD-BACK (GIAB) IN T-CELL DEPLETION ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT)
Authors: LEE CK GINGRICH RD HARMAN GS HOHL RJ SYSEL IA FRANCY RJ AJRAM KA JOHANNSEN SM
Citation: Ck. Lee et al., RISK FACTOR-DEPENDENT MODULATION OF GRAFT-VERSUS-HOST DISEASE (GVHD) BY GRADED INCREMENTAL T-CELL ADD-BACK (GIAB) IN T-CELL DEPLETION ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT), Blood, 88(10), 1996, pp. 1662-1662
REDUCED LETHAL FUNGAL INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT) WITH T-CELL DEPLETION AND ADD-BACK (TCD-AB)
Authors: LEE CK HARMAN GS GINGRICH RD
Citation: Ck. Lee et al., REDUCED LETHAL FUNGAL INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT) WITH T-CELL DEPLETION AND ADD-BACK (TCD-AB), Blood, 88(10), 1996, pp. 1663-1663
TBI-BVAC, AN EFFECTIVE ALLOGENEIC ABLATIVE REGIMEN FOR LYMPHOMA AND MULTIPLE-MYELOMA
Authors: LEE CK GINGRICH RD HARMAN GS HOHL RJ
Citation: Ck. Lee et al., TBI-BVAC, AN EFFECTIVE ALLOGENEIC ABLATIVE REGIMEN FOR LYMPHOMA AND MULTIPLE-MYELOMA, Blood, 88(10), 1996, pp. 2461-2461
COMBINATION CHEMOTHERAPY FOR DISSEMINATED MALIGNANT-MELANOMA
Authors: ABBOTT KL HARMAN GS
Citation: Kl. Abbott et Gs. Harman, COMBINATION CHEMOTHERAPY FOR DISSEMINATED MALIGNANT-MELANOMA, Anti-cancer drugs, 6(4), 1995, pp. 489-497
A PILOT-STUDY OF AUTOLOGOUS MARROW BLOOD STEM-CELL TRANSPLANTATION INTHE TREATMENT NONMETASTATIC INFLAMMATORY BREAST-CANCER/
Authors: GINGRICH RD LEE CK WEN BC HOHL RJ HARMAN GS AJRAM KA
Citation: Rd. Gingrich et al., A PILOT-STUDY OF AUTOLOGOUS MARROW BLOOD STEM-CELL TRANSPLANTATION INTHE TREATMENT NONMETASTATIC INFLAMMATORY BREAST-CANCER/, Blood, 86(10), 1995, pp. 1529-1529
TOXICITY AND OUTCOME OF A NEW HIGH-DOSE, 4-DRUG ABLATIVE REGIMEN COMBINED WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL (HSC) RECONSTITUTION FOR PATIENTS WITH STAGE-IV BREAST-CANCER (ST4BC)
Authors: GINGRICH RD LEE CK WEN BC HARMAN GS AJRAM KA
Citation: Rd. Gingrich et al., TOXICITY AND OUTCOME OF A NEW HIGH-DOSE, 4-DRUG ABLATIVE REGIMEN COMBINED WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL (HSC) RECONSTITUTION FOR PATIENTS WITH STAGE-IV BREAST-CANCER (ST4BC), Blood, 86(10), 1995, pp. 1530-1530
ANTI-CD3 (OKT3) T-CELL DEPLETION AND ADD-BACK (TCD-AB) - COMPARATIVE-ANALYSIS WITH ANTI-CD2 (CT2) TCD-AB IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
Authors: LEE CK GINGRICH RD HARMAN GS HOHL RJ AIRAM KA PADLEY DJ HULING DA TRIGG ME
Citation: Ck. Lee et al., ANTI-CD3 (OKT3) T-CELL DEPLETION AND ADD-BACK (TCD-AB) - COMPARATIVE-ANALYSIS WITH ANTI-CD2 (CT2) TCD-AB IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 86(10), 1995, pp. 2266-2266
EFFECTS OF T-CELL DOSE AND GVHD ON IMMUNE RECONSTITUTION IN CD2 T-CELL DEPLETION AND 2-LEVEL ADD-BACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: LEE CK HARMAN GS HOHL RJ AJRAM KA GINGRICH RD
Citation: Ck. Lee et al., EFFECTS OF T-CELL DOSE AND GVHD ON IMMUNE RECONSTITUTION IN CD2 T-CELL DEPLETION AND 2-LEVEL ADD-BACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION, Blood, 86(10), 1995, pp. 2268-2268
ANTI-CD2 T-CELL DEPLETION WITH 2-LEVEL T-CELL ADDBACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT)
Authors: LEE CK HAYASHI M HARMAN GS HOHL RJ AJRAM KA GINGRICH RD
Citation: Ck. Lee et al., ANTI-CD2 T-CELL DEPLETION WITH 2-LEVEL T-CELL ADDBACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT), Blood, 86(10), 1995, pp. 2269-2269
GRADED, INCREMENTAL DONOR T-CELL ADDBACK (GIAB) FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT)
Authors: GINGRICH RD LEE CK HOHL RD HARMAN GS AIRAM KA
Citation: Rd. Gingrich et al., GRADED, INCREMENTAL DONOR T-CELL ADDBACK (GIAB) FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT), Blood, 86(10), 1995, pp. 2488-2488
PULMONARY VENOOCCLUSIVE DISEASE (PVOD) IN THE ADULT BONE-MARROW TRANSPLANT POPULATION - 2 CASE-REPORTS
Authors: SYSEL IA LEE CK FRANEY RJ HARMAN GS HOHL RJ GINGRICH RD
Citation: Ia. Sysel et al., PULMONARY VENOOCCLUSIVE DISEASE (PVOD) IN THE ADULT BONE-MARROW TRANSPLANT POPULATION - 2 CASE-REPORTS, Blood, 86(10), 1995, pp. 3856-3856
ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) FOLLOWING A CONDITIONINGREGIMEN OF BUSULFAN AND CYCLOPHOSPHAMIDE IN 4 PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH)
Authors: THOMAS AW ACHUS ML HARMAN GS ALLERTON JP CALLANDER NS SNYDER MJ ESSELL JH HALVORSON RD
Citation: Aw. Thomas et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) FOLLOWING A CONDITIONINGREGIMEN OF BUSULFAN AND CYCLOPHOSPHAMIDE IN 4 PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH), Blood, 84(10), 1994, pp. 10000723-10000723
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA, ACUTE LYMPHOCYTIC-LEUKEMIA, AND MULTIPLE-MYELOMA FOLLOWING PREPARATION WITH BUSULFAN AND CYCLOPHOSPHAMIDE (BUCY2)
Authors: COPELAN EA BIGGS JC SZER J THOMPSON JM CRILLEY P BRODSKY I KLEIN JL KAPOOR N HARMAN GS AVALOS BR
Citation: Ea. Copelan et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA, ACUTE LYMPHOCYTIC-LEUKEMIA, AND MULTIPLE-MYELOMA FOLLOWING PREPARATION WITH BUSULFAN AND CYCLOPHOSPHAMIDE (BUCY2), Seminars in oncology, 20(4), 1993, pp. 33-38
Risultati: 1-17 |